IE48851B1 - Microparticle drug delivery system - Google Patents

Abstract

Microparticles for the treatment of the internal female reproductive organs, comprise microparticles of a pharmaceutical agent incorporated in a matrix material which is biocompatible and biologically degradable, said microparticles being capable of being transported after deposition in the vagina by the natural transport mechanism of the internal female reproductive organs across the cervix into the uterus.

Description

The present invention relates to a method for introducing therapeutic or medicinal agents into the uterus and fallopian tubes of the internal female reproductive organs.

In the past, the methods of generally treating the internal 5 reproductive organs of the female have included principally the oral ingestion or the injection of drugs into the patient in order to treat diseases and to regulate the female reproductive cycle. Few methods are known by which the female reproductive organs can be treated by delivery of a therapeutic agent directly to the uterus. One technique wnich achieves the direct delivery of a contraceptive steroid to the uterus is the progestert device which is a medicated intrauterine device. The device is described in U.S. Patent No. 3,699,951 and No. 3,777,015 by Zaffaroni. The disadvantage of the insertable device is that requires a trained physician to place the device in the uterus.. There exists still, therefore, a need for an improved method delivering a contraceptive agent as well as other medicinal -248851 agents such as antigens and antibodies which can be self-administered.

Several·techniques are known by which contraceptive agents in the form of microcapsules can be introduced into the vagina, however, in these techniques transport of the microcapsules across the cervix into the uterus does not occur. For instance, U. S. Patent Nos. 3,918,452 and 3,921,636 show techniques in which a pharmaceutical agent is released from microparticles in a tampon which is placed in the vagina.

The technique shown by Zaffaroni in U. S. Patent Nos. 3,699,951 and 3,777,015 describes an intrauterine device designed to release progesterone directly into the uterus for the purpose of contraception. This device, however, is non-biodegradable and it must be placed in the uterus and removed from the uterus following use by a trained physician. Accordingly, the utility of the device is limited by the fact that it cannot be selfadministered.

Early studies have been conducted to investigate the scope of possible particulate materials which will migrate across the cervix into the uterus after deposition in the vagina. Thus, it -3α 488S1 has been shown that carbon particles from a cap containing a suspension of carbon particles, when placed over the cervix, can be recovered from the uterus after coitus (Amersbach, Sterilitat Und Frigiditat, Muchen. Med. Wchnschr. 77: 225, 1930). J. Trapl, Neuve Anschauunger uber den Ei-und Samentransport in den Geschlechtsteilen de Frau, Zentralbl. Gynak. 67: 547, 19 43, has shown that even without the use of a cervical cap, carmine particles migrate thus demonstrating that nonmotile particles other than carbon also migrate.

Still further, R. Krehbiel and Η. P. Carstens, Roentgen Rabbit, Am. J. Physiol. 125: 571, 1959, have shown that the passage of a radio-opaque oil, when placed in the vagina of a rabbit was blocked until after the vulva was stimulated, while other investigators have shown that graphite and dyes in gelatin were not transported across the cervix. The implication of the data is that the nature of the particles affects the transport process and that transport is assisted by muscular contractions. Hartman, in How Do Sperms Get Into the Uterus? Fertil. and Steril 8: 403, 1957, concluded that in the transport of sperm in the reproductive tract, transport occurs principally by -4« 48851 cooperation of the particles with the musculature of the female reproductive tract. G.M. Duncan and D.R. Kalkwarf, Sustained Release Systems for Fertility Control”, in Human Reproduction: Conception and Contraception, edited by E.S.E. Hafez and T.N. Evans, Harper and Row, New York, 1973, have concluded from experiments that non-motile particles which are about the size of the head of the sperm migrate directionally through the cervix to the fallopian tubes. However, the article shows that progesterone containing microcapsules of cellulose acetate butyrate and of a size ranging from 5 to 1400 pm do not migrate across the cervix into the uterus, but are transported in the reverse direction. Therefore the reference clearly suggests that microcapsules of a size greater than 5 um will not migrate inward to the internal female productive organs.

Gardner et al (Controlled Release Polymeric Formations, Paul and Harris, ACS 33, Chapter 12) proposed that a drug delivery system based upon transcervical migration of particles might make use of microcapsules. They reported the preparation of cellulose acetate butyrate microcapsules of greater than 200 micron diameter containing progesterone or estrone. However, they did not report any attempt to establish if said microcapsules would exhibit transcervical migration. Having regard to Hafez et al, (Supra) and the diameter in excess of 200 microns, it is to be expected that they would not exhibit such migration.

According to a product aspect of the present invention, there is provided an intravaginal preparation containing a pharmaceutical agent and, in addition, a menstrual cycle regulatory hormone for the administration thereof, by transcervical migration, to the internal female reproductive organs, wherein the pharmaceutical agent and the menstrual cycle regulatory hormone are contained in microparticles of a biocompatible and biodegradable matrix and of a size whereby the natural transport mechanism of said internal organs will convey the microparticles across the cervix into the uterus. The invention has particular application when the pharmaceutical agent is (1) an antibody or an antigen and/or (2) a contraceptive agent.

According to another aspect of the present invention, there preparation for use in a is provided a^method of contraception which comprises intra10 vaginally administering to a female in a contraceptive effective amount, microparticles containing a non-abortifacient contraceptive agent in a biocompatible and biodegradable matrix material and being of a size whereby the natural transport mechanism of the internal female reproduction organs will convey the micro15 particles across the cervix into the uterus, and allowing said mechanism to so convey the microparticles whereby the contraceptive agent is directly delivered to the uterus and/or fallopian tubes by subsequent release from said microparticles, where in prior to and/or substantially simultaneously with the intravaginal administration of the contraceptive agent there is intravaginally administered to the female in a menstrual cycle regulatory amount, a menstrual cycle regulatory hormone.

A more complete appreciation of the present invention and many of the attendant advantages thereof will be readily obtained as the same becomes better understood by reference to the following detailed description when considered in connection with the accompanying drawings, wherein: FIGURE 1 shows microparticles of a monolithic structure containing a pharmaceutical agent; FIGURE 2 shows microparticles formed of a core of pharmaceutical agent in a matrix material surrounded by a shell of matrix material; FIGURE 3 shows microparticles formed of a core of pharmaceutical agent surrounded by a shell of matrix material; FIGURE 4 shows microparticles of an onion-skin structure of alternating layers of matrix material and pharmaceutical ig agent; FIGURE 5 shows microparticles formed of a core of one particular pharmaceutical agent surrounded by a shell of matrix material containing a second type of pharmaceutical agent; FIGURE 6 shows monolithic microparticles of contraceptive 15 agent and cycle regulatory hormone in a matrix material; FIGURE 7. shows microparticles of a core of contraceptive agent and cycle regulatory hormone surrounded by a shell of matrix material; FIGURE 8 shows microparticles of a core of contraceptive 20 agent and cycle regulatory hormone in a matrix material surrounded by a shell of matrix material; -748851 FIGURE 9 shows microparticles of a core of contraceptive agent in a matrix material surrounded by a shell of cycle regulatory hormone in matrix material; FIGURE 10 shows multi-layered microparticles in which 5 contraceptive agent and cycle regulatory hormone are dispersed throughout different layers; FIGURES IIA and 11B show the blood' levels of progesterone and estradiol in baboons treated intramuscularly and intravaginally respectively with 7.87 mg of progesterone; FIGURE 12 is a series of photomicrographs showing the histological appearance of baboon endometrium; FIGURE 13 is a series of photomicrographs showing the morphology of the uterine epithelial surface of baboons; FIGURES 14A and 14B show thb blood levels of progesterone 15 and estrogen in baboons treated intramuscularly and intravaginally respectively with 1.57 mg of progesterone; FIGURE 15 is a series of photomicrographs showing the surface epithelial morphology of baboon endometrium; FIGURES 16A and 16B are recordings of the contractile 2o activity of two female baboons one of which was treated with -84-88S1 microparticles containing estradiol and the other of which was not treated with hormone-containing microparticles.

In its broadest terms the objective of the present invention is to provide microparticles containing the specified pharmaceutical agent(s) which when deposited in the vagina are transported by stimulated natural transport mechanism across the cervix into at least the uterus and possibly the fallopian tubes where release of the pharmaceutical agents)occurs.

The microparticle delivery can be employed to convey various antibodies or antigens directly to the internal reproductive organs to obviate systemic introduction of antigens or antibodies for the treatment of the reproductive organs.

Systemic introduction, in fact, cannot be used as a means for administering many antigens and antibodies into the body for treatment of the reproductive organs. In the method aspect of the present invention contraceptive agent-containing microparticles are introduced into the vagina followed by transport of the same across the cervix into the uterus. The direct and local introduction of the contraceptive agent has the advantage that substantially smaller dosages of many types of contraceptive agents can be self-administered to achieve virtually the same contraceptive effect achieved with larger amounts of drug introduced systemically. While the method of the present invention is effective for the delivery of contraceptive agent containing microparticles under normal circumstances in which a woman is regularly cycling, the present method can be modified so that a woman who is not regularly cycling can be regulated and at the same time the internal organs can be rendered increasingly susceptible to transport of the microparticles containing contraceptive agent across the cervix into the uterus and fallopian tubes. The desired effect ls accomplished by incorporating a menstrual cycle regulatory and cervical transport promoting hormone which is normally '5 an estrogen or progestin in the microparticles in addition to the contraceptive agent.

There are two basic ways in which the role of antibodies can be stimulated in the body to counteract the effects of antigens. One technique is active immunization while the other is passive immunization. In order to actively immunize a subject, -104-8851 the subject is administered an antigen to induce the formation of endogeneous antibodies. Normally, this technique requires up to two weeks before a sufficiently good level of antibody response is achieved. Because of the delay involved, the active immunization technique imposes limitations for the treatment of infectious diseases which have a short incubation time, for the treatment of a disease actively in progress and for reversing or modifying the effects of drugs, toxins, hormones, and enzymes. The second basic immunization technique is passive immunization whereby antibodies are administered in order to achieve temporary immune protection. Passive immunization has the advantage that the biological effects are immediate and can be effectively used in patients suffering from immunodeficiency diseases. Moreover, active immunization is not limited to the use of non-toxic antigens because animal species can be used as the source of the protective antibodies. Transport of the microparticles is controlled by the cyclic changes in the endogenous ovarian steroid hormones, estradiol and progesterone. During the first 14 days of the menstrual cycle or the follicular or estrogenic phase of the cycle, the ovaries produce estradiol which has a stimulating effect on the cervical muscle contraction. s. -1148851 The frequency and amplitude of the cervical contractions during the follicular phase steadily increase from day zero to day 14 at which time ovulation occurs and the cycle enters the lutial phase or progestational phase when the ovaries begin to secrete progesterone. Progesterone has an inhibitory effect on the contractile activity of the cervix or alternatively a muscle relaxing effect on the cervix. The ovarian hormones also exhibit an opposing effect in the cells of the cervix in that estradiol causes an accumulation of secretory products in the cells of the cervix while progesterone promotes the release of these products in the cervical lumen. The interactions described are the mechanism by which changes in the viscosity of cervical fluid occur.

The fluid or mucous of the cervix is dynamic and is an aqueous type of hydrogel. The transport of microparticles as well as sperm is dependent upon the permeability of the cervical mucous to the microparticles as well as the propulsion provided by estrogen induced contractions of the cervix. The most appropriate time for transport of microparticles across the cervix occurs when the uterus exhibits maximum contractile activity and -12. 48851 cervical mucous permeability. Accordingly, the greatest rate of transport of sperm or microparticles through the cervix should occur between day 12 and day 16 of the menstrual cycle, although the actual day of ovulation may vary from four to six days in different individuals with some transport occurring in some persons before day 12 of the cycle. Normally, the cervix is not very receptive to transport during the first twelve days of the menstrual cycle as well as between days 16 and 28. Thus, in order to deliver microparticl.es containing antigen, antibody or contraceptive agent into the cervix, the microparticles in an appropriate dosage need only to be deposited in the vagina prior to day 16 of the cycle, preferably before day 12.

In the present invention advantage can be taken of the fact that estrogen and progestin hormaies have a transport stimulating effect on the internal organs. Thus microparticles containing either an estrogen or progestin and medicinal agent or estrogen or progestin containing microparticles with microparticles containing a medicinal agent can be introduced into the vagina to regulate the menstrual cycle of a woman who is not cycling regularly or to stimulate the cervix -13488 51 to transport microparticles across the cervix into the uterus and fallopian tubes. The locally absorbed progestin or estrogen in a biologically effective amount induces the.necessary secretory changes in the endometrium of the cervix and promotes the contractile activity of the cervix necessary for microparticle transport. Once transport activity has begun, the microparticles are conveyed across the cervix into the uterus. Both estrogen and progestin in proper amounts will stimulate transport. However, a progestin at too high a level of concen10 tration will have an adverse effect on microparticle transport because the progestins have a muscle relaxing effect on the tissues of the cervix. However, the adverse effect of the administered progestin can be reversed by the administration of a sufficient concentration of an estrogen via estrogen con15 taining microparticles such asestradiol which as discussed supra induces contratile activity of the tissues of the cervix. Normally, when estradiol is delivered·locally by way of the microparticles, the amount of microparticles administered should be sufficient to deliver from 0.1 to 1 mg per day over a 7-14 day period. On the other hand, when progesterone is incorporated -1448851 in the microparticles, the amount of microparticles administered should be sufficient to deliver from 0.5 to 2 mg per day over a 7-14 day period.

As alluded to above the micro; articles of the present invention can provide the feasibility of locally administering a contraceptive agent,antigen or antibody to the cervix while simultaneously exogenously activating a menstrual cycle in a noncycling woman by the administration of an appropriate ovarian hormone and stimulating the cervix for microparticle transport.

Hence, estrogen containing microparticles can be administered such that estradiol or a synthetic estrogen is released at the cervix for a fourteen day period thus imitating the first half of the menstrual cycle. When transport of the microparticles occurs across the cervix, medicinal agent in the microparticles or in separate microparticles is delivered to the uterus. Fourteen days after administration of the estrogen containing micro particles, progesterone containing microparticles optionally containing antibody or antigen are then administered. Thus, the complete natural menstrual cycle can be imitated while pro20 viding antibody or antigen protection. Of course, it is also -1548851 within the scope of this invention to deliver microparticles containing estrogen or progestin into the cervix to regulate the cycle and thereafter administer antigen or antibody containing microparticles at the period of the cycle when the cervix is 5 receptive to transport. In tne imitated (i.e. artificially induced) cycle maximum transport across the cervix is achieved between days 12 and 16. Since the cycle regulatory hormones are administered locally in the present technique, effective estradiol activity can be achieved at dosage rates between 0.01 and 0.07 mg per day, while effective progesterone activity can be attained at dosage rates of 0.04 to 0.14 mg per day. Estradiol and progesterone are the regulatory hormones of choice. However, it is evident that other well known synthetic estrogens and progestins can be employed as substitutes for estradiol and progesterone, respect15 ively. Suitable estrogens include estrone, mestranol, ethinyl estradiol, 2-methoxyestrone, 2x-hydroxyestrone and estriol. Suitable progestins include norethindrone, dimethisterone, ethynodiol diacetate, norethynodiol, norethindrone acetate and norges· trol. When the synthetic compounds are employed, the dose employed depends entirely upon the biological potency of the synthetic estrogen or progestin compound.

Microparticles containing a medicinal agent such as antibody, antigen or contraceptive agent and/or menstrual cycle regulating -1648851 hormone can be formed in a variety of configurations. In perhaps the simplest situation shown in FIGURES 1 and 6 microparticles of a monolithic structure are prepared in which the desired antigen or antibody 2 on the one hand, or contraceptive agent 21 and cycle regulatory hormone 22 on the other hand, is distributed throughout a matrix material 1 (or 23) which is biodegradable and biocompatible. Once the microparticles are deposited in the vagina they begin to slowly deteriorate thereby continuously releasing the desired drug to achieve the desired daily dosage of drug over a prolonged period of time from the time they are deposited in the vagina until well after the microparticles have been conveyed across the cervix and deposited in the uterus. When the microparticles contain a cycle regulatory hormone, continuous release of the hormone regulates the Dro15 perties of the cervical mucous.and the contractile activity of the cervix. Since the microparticles of this particular embodiment continually release their active constituents from the time of deposition in the vagina, it is evident that most • convenient results are achieved if the microparticles are formed such that they have an effective lifetime close to the period of the menstrual cycle so that microparticles need only be -1748851 administered once during the cycle. However, this is only a preferred embodiment because the microparticles can be administered as many times as desired to achieve contraceptive and cycle regulatory effects.

FIGURE 2 shows another embodiment of the microparticles of a monolithic structure wherein antigen or antibody 2 is incorporated within matrix material 1 which in turn is surrounded by an envelope 3 of a drug free matrix material. This type of microparticle configuration wherein the particles are of a size such that they possess sperm surrogate activity, is desirable where release of drug is to be delayed for some period of time after deposition of the microparticles in the vagina. The delayed release of drug obtained by using the above microparticles, for instance, would allow sufficient time for the micro15 particles to be deposited in the vagina, transported across the cervix and deposited in the uterus before the microparticles deteriorate to the point where the outer wall is essentially eliminated and drug release commences.

FIGURE 7 shows microparticles in which a core 25 of contraceptive agent 21 and cycle regulatory hormone -1848851 is encapsulated in a shell 27 of matrix material 24. This particular configuration of microparticles would be desirable where it is necessary to delay release of the active constituents of the deposited microparticles as described above for the microparticles of FIGURE 2.

In still another microparticle configuration as shown .in FIGURE 3, the microparticles can be designed for the sudden release of a large amount of antibody or antigen. To achieve this purpose the microparticles can be formed such that a core of antigen or antibody is encapsulated in a shell matrix material 1. Microparticles containing a core of drug would be particularly well suited in situations where an endogenous factor for disrupting the outer shell of the microparticles is exploited. For example, the difference in pH of the mucosal fluids in the vagina on the one hand,.and the cervix and uterus on' the other hand, can be exploited such that deterioration of the outer shell occurs when the microparticles reach the area of the cervix or uterus. In this situation, the acidic pH of the vagina would have little or no effect on the shell of the microparticles. However, when the microparticles are conveyed -1948851 into the cervix where they are exposed to the neutral pH therein, breakdown of the outer shell would commence eventually resulting in the sudden release of drug which is advantageous where it is desirable to deliver a substantial amount Of antibody to a patient suffering from an acute infection or having a high concentration of toxin. This procedure would be particularly desirable where it is desired to administer a booster response after an individual has already received a primary immunization.

In the treatment of patients for some disorders it is advantageous to be able to administer antigen or antibody in an intermittent fashion. This could be accomplished by the use of microparticles having the configuration shown in FIGURE 4 where alternate layers of drug alone or dispersed in matrix material 7 and drug free matrix material 1 are formed in concentric layers. When such microparticles are deposited in the vagina, release of drug does not occur until the outer layer of the microparticles disintegrates. Once the underlying layer is exposed drug release starts and continues until the layer disintegrates or releases the drug. Drug release ceases as the next underlying drug free layer is reached. In this manner intermittent release of the drug is achieved. An example of the -2048851 applicability of this technique can be found in active immunization where the outermost drug layer releases antigen for a sustained period which is followed by a period for instance of a week or two, in which no drug is released. After the non5 drug containing layer disintegrates, a second period of antigen release starts. In this manner one could in a single administration of microparticles provide a primary immunization dose followed by a booster dose.

It is possible to administer microparticles of a monolithic structure as shown in FIGURE 1 in which both antigen or antibody and cycle regulating hormone are dispersed through a matrix material. In this manner, once the microparticles are deposited in the vagina, release of both hormone and antigen or antibody starts and eventually the microparticles are conveyed across the cervis into the uterus. A perhaps more selective regimen of administration could be provided by microparticles which have an outermost matrix layer containing cycle regulatory hormone and an inner core of matrix material containing antigen or antibody. When such microparticles are administered, the sustained release of cycle regulatory hormone occurs, and when the cervix is receptive to transport, the .microparticles are transported across the cervix into the uterus. Release of the antigen or antibody will occur in the cervix or uterus as the underlying antigen or antibody core of the microparticles is exposed. FIGURE 5 shows microparticles of the structure dis-, cussed above in which outer cycle regulatory hormone containing layer 9 encapsulates inner antigen or antibody containing core 11. The antigen or antibody alone can constitute the core of the microparticles or the antibody or antigen can be dispersed inthe matrix material to form core 11. However, outer layer or shell 9 is formulated by dispersing a menstrual cycle regulatory hormone in a matrix material.

From the above discussion it is evident that antibody or antigen alone or in combination with a cycle regulatory hormone can be incorporated in microparticles in a variety of configurations depending upon how the drug or drugs are to be released.

Moreover, while multi-layered microparticles such as the types shown in FIGURES 2, 4 and 5 are normally formed of a .single type of matrix material, it is possible, if not desirable under -22sessi some circumstances, to formulate contiguous layers of the microparticles from different matrix materials. Still further, it is possible that under some circumstances, it may be desirable to deliver more than one antibody or antigen to the internal repro5 ductive organs to treat more than one condition. Thus, for instance, monolithic microparticles could be prepared and delivered containing two different antibodies to passively treat two different diseases. In fact, it may be desirable under some circumstances to actively immunize a patient against one dis10 order and simultaneously passively immunize the patient against a second disorder with antigen or antibody delivered in the same microparticles. Of course, when more than one antigen and/ or antibody is combined in one microparticle where they may be in contact and not in different layers of a microparticle, they must not react with each other.

Still another microparticle configuration is shown in FIGURE 8 wherein compatible, i.e. mutually non-reAc.tive, contraceptive agent 21 and cycle regulatory hormone 22 are dispersed in matrix material 23 to form a core 25. The microparticles are completed by encapsulating the particles of drug containing matrix material in a shell 27 of matrix material 24. The matrix material 23 and 24 of the inner core 25 and shell 27 can be the same material or different material. The use of different matrix materials is especially useful where it is desired to take advantage of the different rates of deterioration of the matrix materials or the different rates of diffusion of the drug through the matrix materials. Release of the contraceptive agent and cycle regulatory hormone does not occur until the shell of matrix material 24 has deteriorated.

FIGURE 9 shows a microparticle structure wherein a core of contraceptive agent 21 in matrix material 23 is formed and then in turn core 25 is surrounded by a shell 27 of matrix material 25 containing cycle regulatory hormone 22. The microparticles of this particular configuration are especially use15 ful where it is desired to deposit microparticles in the vagina to achieve the initial gradual release of only cycle regulatory hormone 22 which regulates the monthly cycle and stimulates transport of the microparticles across the cervix. In this manner regulation of the monthly cycle and at least initial transport of the microparticles can be initiated by the time the inner core 25 is sufficiently exposed to permit release of encapsulated contraceptive agent 21. Of course,the contraceptive -24' 48851 agent can be encapsulated alone or dispersed throughout a core matrix material which can be the same as or different from shell matrix material 24.

A multiply layered microparticle configuration is shown in FIGURE 10. These microparticles possess an inner core 25 of a contraceptive agent 21 alone or dispersed in a matrix material 23. The core 25 is encapsulated in a shell 27 of a matrix material 24 which in turn is encapsulated in an outer shell 31 of matrix material 29 containing cycle regulatory hormone 28.

Microparticles of this particular configuration would be useful in those situations where it is desirable to administer cycle regulatory hormone after deposition of the microparticles in the vagina. After all of the cycle regulatory hormone has been released, release of the contraceptive agent would be delayed until inner shell 27 has deteriorated to a sufficient extent to permit release of contraceptive agent from core 25. In the meantime, transport of the microparticles will occur thus achieving delayed release of the contraceptive agent until the bulk of the microparticles has been conveyed into the uterus.

With regard to the physical shape of the I -254 8 8 51 microparticles, the microparticles can assume any possible shape ranging from ordered shapes such as spherical or oval to irregular shapes. The shape of the microparticles is not a factor in microparticle transport. Normally, the medicinal agent diffuses from the microparticles by gradual deterioration of the matrix material and/or by permeation of the agent from the matrix material.

The size of the microparticles is important insofar as the microparticles must possess sperm surrogate activity such that they can be conveyed by the natural transport mechanism of the reproductive organs upward from the cervix into the uterus and eventually into the fallopian tubes. If the microparticles are too large, they will cause contractions of the cervix which will expel the microparticles. Microparticles which are too small will not be conveyed upward into the internal reproductive organs. Usually, the microparticles range in size 20 to 70μΐη5 preferably 20-60 pm.

The matrix material from which the microparticles are formed and in which the contraceptive agent and cycle regulatory hormone are dispersed is important not only from the viewpoint -2648851 of sperm surrogate activity but also from the biocompatibility standpoint. In order for a material to be acceptable as a matrix material it should have no adverse effect on the internal female reproductive organs. The matrix material should also be biocompatible. By biocompatible is meant that the material does not irritate the tissues of the cervix or uterus, is not carcinogenic, does not induce inflammation in body tissues, is compatible with body tissues and is miscible with the cervical mucous. Another factor of importance is that the matrix material must be biodegradable. By biogradable is meant that body chemical processes are able to eventually breakdown the matrix material so that it does not accumulate in the body and that the matrix material has the ability, when in microparticle form, to slowly deteriorate over a period of time which at least corresponds to the female monthly menstrual cycle. Suitable examples of matrix materials include polyglycolic acid, d,l-polylactic acid, copolymers thereof, and the like. Other useful matrix materials include such materials as glycerol mono- and di stearate. Other matrix materials include those which will decompose in the neutral environment of the cervix· Suitable types of antigens which can be incorporated in the present microparticles include bacterial and viral pathogens of man and animals, however, enzymes and other biological factors involved in the reproductive process can also be used. Suitable pathogenic antigens 5 include Neisseria gonorrhea, Mycobacterium tuberculosis,' Herpes virus (humonis, types 1 and 2), Candida albicans, Candida tropicalis, Trichomonas vaginalis, Haemophilus vaginalis, Group B streptococcus ecoli, Microplasma hominis, Hemophilus ducreyi. Granuloma inguinale, Lymphopathia venereum, Treponema pallidum, Brucella abortus. Brucella melitensis, Brucella suis. Brucella canis, Campylobacter fetus, Campylobacter fetus intestinalis, Leptospira pomona, Listeria monocytogenes, Brucella ovis, Equine herpes virus 1, Equine arteritis virus, IBR-XBP virus, BVD-MB virus, Chlamydia psittaci. Trichomonas foetus, Toxo15 plasma gondii, Escherichia coli, Actinobacillus eguuli, abortus ovis, Salmonella abortus equi, Pseudomonas aeruginosa, Corynebacterium egui, Corynebacterium pyogenes, Actinobaccilus seminis, Mycoplasma bovigenitalium, Aspergillus fumigatus, -2848851 Absidia ramosa, Trypanosoma equiperdum, Babesia caballi, Clostridium tetani.

Suitable examples of enzymes that may be involved in the reproductive process include ribonuclease, neuramidinase, trypsin, glycogen phosphorylase, sperm lactic dehydrogenase, sperm hyaluronidase, adenosinetriphosphatase, alkaline phosphatase, phosphatase esterase, amino peptidase, trypsin chymotrypsin, amylase, muramidase, acrosomal proteinase, diesterase, glutamic acid dehydrogenase, succinic acid dehydrogenase, beta-glycophosphatase, lipase, ATP-ase alpha-peptate gamma-glutamylotrans peptidase, sterol-3-beta-ol-dehydrogenase, DPN-di-aprorase.

Suitable examples of hormones acting as antigens include human chorionic gonadotrophin ^hormones, human placental lactogen, progesterone, estradiol and the like. Other antigens include those known as embryonic cellular antigens which occur on the cellular surface of the trophoblast and are unique to the trophoblast. In addition to the above mentioned pathogens, mixtures of pathogens which can infect the female reproductive organs also can be incorporated in microparticles.

Examples of antibodies for passive immunization which can -29be incorporated in microparticles include those which correspond to all of the above described antigens which are effective for active immunization. Antibodies which are effective against sperm, eggs, products of conception and the like can also be employed.

When the antigen or antibody containing microparticles are administered to a subject, they are administered in an amount such that the desired daily dosage level of antigen or antibody is delivered in an amount sufficient to elicit the desired response over the desired period of time, which for antigen would be about 0.5 to 1 mg of antigen per day over a 7-14 day period. The dosage range required for a booster immunization would vary from 0.5 to 1 mg per day over a 24 hour time span. With regard to*passive immunization via antibody administration, the weight of antibody administered does not necessarily directly relate to the therapeutic effect realized. The important factor in terms of dosage for passive immunization is the titer of the antibody or the biological potency. The titer of an antibody refers to the maximum dilution of the anti20 body which elicits an effect in a test situation. Two different -3048851 preparations of antibody are not equally comparable on a weight basis because they have different biological potencies. An immunological titer of 1:500 is the minimum biological potency for any antibody to be administered by the process of the present invention. Moreover, the rate at which the immunoglobulin or antibody should be delivered to the cervix, uterus and fallopian tubes should not exceed 0.1 mg of antibody per day.

Any dose rate less than this level which is effective in eliciting a therapeutic response is acceptable.

The antigen, antibody or contraceptive agent containing microparticles can be conveniently prepared by any well known procedure used in the past for the preparation of microparticles containing a pharmaceutical material. While the amount of antigen or antibody, and cycle* regulatory hormone, if it is to be present, is not critical, normally, the microparticles contain frpm about 10 wt,. % to 60 wt.% preferably 10 wt.% to 50 wt.%, most preferably 10 wt.% to 25 wt.% of antibody or antigen.

The primary limitation for the generation of passive immunization in a subject by the administration of antibodies in clinical medicine is that antibodies produced in animals often cause serum sickness or anaphylaxis when injected into -314 8851 human recipients. However, the local delivery technique of the present invention circumvents this problem because not-only are smaller dosages of antibodies required, but also systemic administration of antibodies is avoided.

In some instances active immunization is more advantageous than passive immunization such as for permanent protection against infectious diseases. Thus, when an antigen is delivered to the uterus and fallopian tube by the present technique, antibodies are secreted which not only provide the desired immunological effect, but also are structurally and fundamentally unique from the type of antibody produced in response to systemic immunization. Systemic antibodies are not secreted by the reproductive organs, and it is for this reasori that systemic immunization is not an effective way of generating antibodies in the fluids of the cervix, uterus and fallopian tubes.

Another aspect of active immunization pertains to fertility In this case, sperm antigens are delivered by transport of antigen containing microcapsules into the cervix, uterus and fallopian tubes. The antigen which is slowly released over a sustained period of time, stimulates the secretory tissues of the organs -3248851 to secrete protective antibodies in the fluid layer which coats the internal organs which essentially are the. cervix, uterus · fallopian tubes. After copulation and deposition of sperm in the vagina, antibodies in the cervical mucous cause -agglutination of the sperm in the cervix and prevent further transport of the sperm into the uterus. Antibodies against sperm also inactivate sperm by techniques other, than agglutination.

For the contraceptive agent containing microparticles of the invention any type of contraceptive agent which has the desired contraceptive effect, especially in mammals, can be formulated in the present microparticles. Suitable examples of contraceptive agents include spermicidal compounds such as nonylphenoxypolyoxyethylene ethynol, Benzethonium chloride (benzyldimethyl [(2-(1, 1, 3,3-tetramethylbutyl-phenoxy) ethoxy) ethyl] ammonium chloride), Chlorindanol (7-chloro-4-indanol) and the like; and natural and synthetic hormones such as Progesterone (4 4-pregnene-3, 20-dione), Estradiol (estradiol 3, 17β -dicypionate), Norethindrone (17-hydroxy-19-nor-17°1^ -ethynyl 17β- hydroxy -4-en-3-one), Ethynodiol diacetate (3β , 17β -3348851 diacetoxy-17 c<-ethynyl-4-estrene), Lynestrenol (17^-ethynylestr4-en-17/) -ol), Medroxy-progesterone acetate (17β -hydroxy-6 °Cmethylpregn-4-ene-3, 20-dione), Dimethisterone (17β -hydroxy6 c<-methyl-17-l-propynyl-androst-4-en-3-one), Megestrol acetate (17 -hydroxy-6-methylpregn-4, 6-diene-3, 20 dione acetate), Chlormadinone acetate (6-chloro-17-hydroxy-pregna-4, 6-diene-3, 20-dione acetate), Ethinylestradiol (17c<-ethinyl-1,3,5(10)estratriene 3β -diol), Mestranol (3-methoxy-19-nor-17°C-pregna1, 3, 5(10)-trien-20-yn-17-ol) and the like. Another class of compounds within the scope of the present invention are those which induce early abortion in mammals. Suitable examples of compounds possessing abortifacient activity include antihistaminesj cytotoxic drugs, ergot alkaloids, hormones, prostaglandins such as Prostaglandins E2 and F2 The amount or microparticles deposited in the vagina depends upon the amount of contraceptive agent that must be -3448851 delivered to the uterus and fallopian tubes to achieve the desired contraceptive effect. In the case of hormones which produce a contraceptive effect, the dosage of hormone which should be administered ranges from 20 ug to 1000 ug, especially 100 ug to 1000 ug, per day. In the case of spermicidal contraceptive agents it is not necessary to administer a daily dosage over most of the days of the menstrual cycle. It is only necessary to administer spermicidal aqent for several days around midcycle when conception is possible at a dosage level sufficient to prevent con10 ception. Normally, a dosage of 25u9 to 1000 u9 per day for 7 days about midcycle will achieve the desired effect. Other types of contraceptive agents which can be used as discussed above include abortifacient drugs. These abortifacient drugs should be administered immediately following a missed menstrual period for three to five days at a dose of 1 to 590 mg per day.

In the manufacture of the microparticles containing antigen or antibody and for a menstrual cycle regulatory hormone, any conventional method of forming the microparticles can be used. The selection of a particular method chiefly depends upon the technical requirements of the matrix material and the -3548851 particular manner in which the microparticles are intended to be used. Generally, microencapsulation processes can be classified according to the three principal types, (1) phaseseparation methods including aqueous and organic phase separa5 tion processes, melt dispersion and spray drying; (2) interfacial reactions including interfacial polymerization, in situ polymerization and chemical vapor depositions; and (3) physical methods, including fluidized-bed spray coating, multi- and single-orifice centrifugal coating, electrostatic coating and physical vapor deposition.

Microparticles containing medicinal or therapeutic agents can be delivered to the vagina by a variety of methods. The preferred method is to incorporate a fixed number of microparticles into a container designed for easy hand insertion into the vagina. The insertion container should be made of a biodegradable material that dissolves within minutes after placement in the vagina, thus, releasing the microparticles.Pharmaceutical type gelatin capsules can be conveniently used as a delivery system for the microparticles.The dose level can be varied by increasing or decreasing the number of microparticles in the delivery device. -3648851 Of course, any number of other methods of variations, or this preferred method might be used. For example the microparticles could be molded into a solid vaginal suppository which affords the simplest most direct method of applying the microparticles by using an appropriate suspension medium such as gelatin.

Creams, jellies, foams, or liquids might be used as a suspension medium for microparticles. Preparations of this type could be placed in the vagina using a loadable syringe or some type of pressurized vaginal inserter such as an aerosol device or a squeeze tube or bulb. A variety of different types of applicators for administering pharmaceutical agents to the vagina and rectum are in common use. A gelatin capsule is also a convenient vehicle for the delivery of microparticles.

Having now generally described the invention, a more com15 plete understanding can be obtained by reference to certain specific examples which are included for purposes of illustration only and are not intended to be limiting unless otherwise specified. -3748851 EXAMPLE 1 Preparation of Progesterone Containing Polylactic acid Microcapsules A 2.5 g amount of progesterone and 10.0 grains of d,l-poly5 lactic acid were dissolved in 38 grains of methylene chloride.

The resulting viscous solution was poured into a 250 ml kettle containing 120 ml of a 5 wt.% aqueous polyvinylalcohol solution. The dispersion obtained was stirred at about 200 rpm until a stable emulsion had formed with the droplets being in the range of 50 to 100 pm in diameter. A vacuum was applied to the emulsion until it began to foam and then the rate of stirring was reduced to 600 rpm. After two hours, most of the methylene chloride had evaporated. Moreover, continuous stirring was not required to prevent the embryonic microcapsules from agglomerating. There15 after, the emulsion was centrifuged, the aqueous polyvinylalcohol solution was decanted and the microcapsules were resuspended in 150 ml of deionized water. For about 18 hours thereafter a vacuum was continually applied to the stirred aqueous suspension. Thereafter, the suspension was centrifuged and the microcapsules obtained were washed with water and then collected by vacuum filtration. The microcapsules were dried at room temperature under a hard vacuum overnight, and then they were sieved whereby -384 8 8 51 a fraction ranging between 43 and 61 was obtained. By this procedure microcapsules containing 22 + 1.5 wt.% progesterone were obtained.

EXAMPLE 2 Preparation of Progesterone Containing Glycerol Monosi-earate Microcapsules A 1,0 gram amount of progesterone was added to 4 grams of molten glycerol monostearate and a portion of the molten mixture was poured into the reservoir.of a melt sprayer and heated to 167°C. The flow of nitrogen into the device to effect cooling was 60 liters per minute, while the flow of nitrogen into the sprayer to aerosolyze the molten mixture was adjusted to the maximum rate of 5.57 liters per minute. The aerosol was sprayed intermittently, and microcapsules were collected and sieved, whereby a size fraction ranging between 43 and 61 pm was collected. The microcapsules produced by this procedure were spherical and contained a 20 wt.% theoretical loading of progesterone.

EXAMPLE 3 Fotfr female baboons were injected with d, 1-polylactic -3948851 microcapsules containing 7.87 mg of progesterone while five baboons were treated with d,1-polylactic microcapsules contain ing 7.87 mg of progesterone by the vaginal route of administration. All baboons were treated on day 5 and uterine biopsies were taken on day 12. Daily blood levels of estradiol and progesterone were also obtained. The results of the daily determinations are shown in FIGURE 11 wherein FIGURE 11A shews the level of progesterone and estradiol for the intramuscular injection of microcapsules while FIGURE 11B shows the levels of progesterone and estradiol for the vaginal administration of microcapsules. It is apparent that higher blood level concentra tions of progesterone are found in the intramuscularly injected baboons than in vaginally treated baboons. There are two possibilities to account for this: (1) not all of the micro15 capsules placed in the vagina remain in the body over the 7-dav period of treatment; (2) not all progesterone released from the microcapsules following placement in the vagina reaches the bloodstream. Both of these possibilities probably contribute to the differences in the systemic levels of progesterone between 0 the two treatment groups.. If systemic delivery of progestei'one -4048851 is considered alone and the possibility of local delivery directly to the uterus in the intravaginally treated animals is excluded, it is logical to expect a more intense progestational effect in baboons treated by injection than in those treated vaginally. The results from dose-response experiments support this expectation. Comparative histological examination of the endometrial biopsies of the baboons, however, do not support this assumption. Histological examination reveals no significant reduction in the level of progesterone-induced secretory activity in baboons treated by intravaginal administration when compared to those treated by intramuscular injection. This is somewhat unexpected on the basis of the difference in the systemic levels of progesterone. This seemingly contradictory finding actually supports the possibility for local delivery of progesterone in the vaginally treated baboons.

FIGURES 12a and 12b show the histological appearance of the endometrium of a baboon treated by the intravaginal administration of microcapsules containing 7.87 mg of progesterone (H S R stained tissue at 20x and lOOx magnification, respectively).

FIGURES 12c and 12d represent the same tissue (PAS stained) at -4148851 20x and lOOx magnification, respectively.

A second line of histological evidence which provides support for the local delivery of progesterone in the vaginaHy treated animals comes from the observation that progesterone5 induced alterations in endometrial histology are distributed evenly throughout the endometrium in baboons treated by injections; whereas, in baboons treated by intravaginal deposition of the microcapsules, the effects are localized and vary from gland to gland with a notable intensity of stimulation in the superficial glands underlining the surface epithelium (FIGURE 12). The absence of subnuclear vacuoles in the superficial glands in baboons treated by injection and the abundant presence of subnuclear vacuoles in the superficial glands of baboons treated intravaginally provides evidence of the local intrauterine delivery of progesterone in the intravaginallytreated baboons.

A comparative examination of the surface epithelial morpho logy by scanning electron microscopy provides further evidence for localized progestational effects following intravaginal treatment with the microcapsules. FIGURE 13 compares the -4248851 morphology of the uterine epithelial surface of: normal nontreated day 12 baboon endometrium (FIGURE 13a); normal nontreated day 20 endometrium (FIGURE 13b); treated day 12 endometrium (intramuscular injection of microcapsules containing 7.87 mg of progesterone, FIGURE 13c); and treated day 12 endometrium (intravaginal deposition of microcapsules containing 7.87 mg of progesterone, FIGURE 13d).

Progesterone induces the formation of distinct microvillus projections on the luminal surface of the glandular epithelial cells. Microvilli are not normally present before ovulation (see day 12 control) but become quite conspicuous after ovulation (see day 20 control). Continuous progesterone treatment between days 5 and 12 induces the formation of numerous microvillus projections. Microvilli occur in ^n even distribution on the epithelial surfaces of baboons treated by injection. However, in baboons treated intravaginally the microvilli occur in distinct patches. The patchy uneven distribution of microcapsules occurs betwee· areas in which the epithelial cells lack microvilli and other areas in which the microvilli vary in size. This uneven distribution of a progesterone-induced alteration in the morphology of the surface epithelium is indicative of localized areas of progesterone stimulation. Following systemic delivery. -434 8851 all areas of the endometrium receive a uniform dose of drug, whereas with local delivery, some areas may receive higher or lower doses depending on where the microcapsules are located within the uterus.

FIGURES 14A and 14B compare the mean progesterone and estradiol levels between baboons treated by either intramuscular injection (FIGURE 14A) or intravaginal administration (FIGURE 14B) with a dose of microcapsules containing 1.57 mg of progesterone under the conditions described above. This low dose of microcapsules has a slight inhibiting effect on the estradiol levels when administered by injection and no effect when administered intravaginally. Exogenous progesterone is present in low levels in the blood between days 5 and 12 in baboons treated by injection. However, in baboons treated by the vaginal route, exogenous progesterone could not be detected in the blood within the sensitivity range of the assay technique between days 5 and 12.

On the basis of the comparative hormone data shown in FIGURE 14 and excluding the possibility for local delivery, it seems logical to expect the histology of the endometrium of the -4448851 vaginally-treated baboons to resemble the pattern observed in normal non-treated controls. The rationale for this expectation is that the blood levels of both progesterone and estradiol in baboons treated by the intravaginal route with the low dose of microcapsules is identical to that which occurs normally.

Therefore, on the basis of endocrine data , there is little reason to expect hormone-induced alterations in the endometrial histology. The same rationale, however, does not hold for the animals treated by injection because following the treatment, detectable progesterone levels were found in the blood between days 5 and 12. Moreover, the estradiol levels appear to be somewhat depressed when compared to the normal controls. Again, the histological findings are contrary to the expected results. In spite of the lack of measurable systemic progesterone in baboons treated by the vaginal route, the endometrium exhibits distinct progestational effects.

Examination of the surface epithelial morphology by scanning electron microscopy reveals the frequent occurrence of microvilli providing clear evidence for progesterone stimula20 tion as shown in FIGURE 15. Xn particular, FIGURES 15a and 15b il -45I 488-51 are low magnification (9600) and high magnification (18240) micrographs of the surface epithelium of the treated baboon on day 12 of the menstrual cycle. FIGURE 15c is a micrograph of the epithelium which shows microcapsules containing progesterone on the surface of the epithelium while FIGURE 15d is a photomicrograph of the microcapsules themselves. Although the progesterone-induced alterations in the endometrial histology might occur in response to systemic progesterone that is too low to measure by the assaying system employed, a more likely explanation is that the progesterone-induced changes result from direct local intrauterine delivery of progesterone. · The most important point to emphasize is; that with a low dose of microcapsules (i.e., 7.87 mg of progesterone) secretory changes were induced-in the endometrium. Moreover, a dose response associated with the changes has been demonstrated suggesting that by increasing the dose it should be possible to achieve a level of effect sufficient to inhibit reproductive function.

FIGURES 16A and 16B compare the pattern of cervical muscle contractile activity between two baboons on the same day of the -4648851 menstrual cycle. A special transducer constructed as described by W. D. Blair and L. R. Beck in Ovum Transport and Fertility Regulation, 1976, pp. 41-74, Scriptor Publication (Copenhagen) placed in the cervix of each baboon was used to measure the pattern of the cervical contractions shown in the Figures. The transducer was connected to a strip chart recorder. FIGURE 16A shows the results obtained from a baboon treated by placing microparticles containing estradiol into the vagina while FIGURE 16B shows the results obtained from a control baboon untreated with microparticles. The results show that the treatment stimulates both the frequency and the amplitude of the cervical contractions. These contractions move the microparticles through the system.

Having now fully described the invention, it will be apparent to one of ordinary skill in the art that many changes and modifications can be made thereto without departing from the scope of the invention as defined in the following claims.

Claims (10)

1. An intravaginal preparation containing a pharmaceutical agent and, in addition, a menstrual cycle regulatory hormone for the administrat ion thereof, by transcervical migration, to the internal female reprod5 uctive organs, wherein the pharmaceutical agent and the menstrual cycle regulatory hormone are contained in microparticles of a biocompatible and biodegradable matrix material and of a size whereby the natural transport mechanism of said internal organs will convey the microparticles across the cervix into the uterus. 10

2. A preparation as claimed in Claim 1 which consists of the microparticles per se.

3. A preparation as claimed in Claim 1 wherein the microparticles are contained in a biodegradable capsule insertable into, and degradable in, the vagina to release the microparticles in the vagina. 15

4. A preparation as claimed in Claim 3 wherein the capsule is a gelatin capsule. 5. The uterus and/or fallopian tubes where said contraceptive agent is released. 55.A preparation as claimed in Claim 54 wherein said estrogen is released from said microparticles at a rate of 0.1 to 1 mg per day and wherein said progestin is released 5 said microparticles, wherein prior to and/or substantially simultaneously with the intravaginal administration of the contraceptive agent there is intravaginally administered to the female in a menstrual cycle regulatory amount, a menstrual cycle regulatory hormone. 10 41. A preparation as claimed in Claim 40 wherein the contraceptive agent is a spermicidal compound. 42. A preparation as claimed in Claim 41 wherein the spermidical compound is nonylphenoxypolyoxyethylene ethynol, Benzethonium chloride or Chlorindanol. 15 43. A preparation as claimed in Claim 41 or Claim 42 wherein the said microparticles are administered to release the spermicidal compound in the uterus and/or fallopian tubes only over a midmenstrual cycle period of several days. 44. A preparation as claimed in Claim 43 wherein the spermicidal 20 compound is released for a period of about 7 days at a dosage in the range 25 to 1000 micrograms per day. 45. A preparation as claimed in Claim 40 wherein the contraceptive agent is a hormone different from said menstrual cycle regulatory hormone. 25 46. A preparation as claimed in Claim 45 wherein the hormone is progesterone, estradiol, norethindrone, norgestrel, ethynodiol di acetate, lynesterenol, medroxy-progesterone acetate, dimethisterone, megestrol acetate, chlormadinone acetate, ethinyl estradiol ormestranol. 47. A preparation as claimed in Claim 45 or Claim 46 wherein the said microcapsules are administered to release the hormone in the uterus and/or fallopian tubes at a dosage in the range 20 to 1000 micrograms per day. 48. A preparation as claimed in Claim 47 wherein the said dosage is in the range 100 to 1000 micrograms per day. 49. A preparation as claimed in any one of Claims 46 to 48 wherein the hormone is estradiol and/or progesterone. 50. A preparation as claimed in any one of Claims 40 to 49 wherein at least a portion of said menstrual cycle regulatory hormone is administered in the form of microparticles as specified in any one of Claims 1 and 3 to 10. 51. A preparation as claimed in Claim 50 wherein at least a proportion of said microparticles contain both the contraceptive agent and the menstrual cycle regulatory hormone. 52. A preparation as claimed in any one of Claims 47 to 51 wherein the menstrual cycle regulatory hormone is an estrogen or a progestin. 53. A preparation as claimed in Claim 52 wherein said estrogen or progestin is estradiol or progesterone. 54. A preparation as claimed in Claim 52 or Claim 53 comprising depositing estrogen containing microparticles in the vagina where estrogen is steadily released thereby duplicating days 1 to 14 of the estrogenic phase of the menstrual cycle and rendering the cervix increasingly capable of microparticle transport; depositing progestin containing microparticles in the vagina where said progestin is released after day 14 to day 28 of said cycle thereby duplicating the progestational phase of said cycle; and depositing the said microparticles containing said contraceptive agent in the vagina in time sufficient for the maximum transport of said contraceptive agent containing microparticles between days 12 and 16 of said cycle across the cervix into 5 acetate, ethinyl estradiol or mestranol. 22. A preparation as claimed in Claim 11 wherein the contraceptive agent is an abortifacient compound. 23. A preparation as claimed in any one of the preceding claims wherein the menstrual cycle regulatory hormone is an estrogen 10 or a progestin. 24. A preparation as claimed in Claim 23 wherein the estrogen or progestin is estradiol or progesterone. 25. A preparation as claimed in any one of the preceding claims wherein the pharmaceutical agent and the menstrual cycle 15 regulatory hormone are contained in the same microparticles. 26. A preparation as claimed in any one of the preceding claims wherein all the said microparticles contain the same active components. 27. A preparation as claimed in any one of Claims 1 to 24 20 comprising at least two classes of said microparticles which classes contain a different active components or combination of active components. 28. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in 25 Figure 1. 29. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 2. 30. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 3. 31. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 4. 32. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 5. 33. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 6. 34. A preparation as claimed in Claim 1 substantially as described with reference to Figure 7. 35. A preparation as claimed in Claim 1 substantially as described with reference to Figure 8. comprising microparticles and as shown in comprising microparticles and as shown in 36. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 9. 37. A preparation as claimed in Claim 1 comprising microparticles substantially as described with reference to and as shown in Figure 10. 38. A preparation as claimed in Claim 1 comprising microparticles as hereinbefore described in Example 1. 39. A preparation as claimed in Claim 1 comprising microparticles as hereinbefore described in Example 2. 40. A preparation as claimed in any of the pregeding c]aims for use in a method of contraception which comprises intravaginally administering to a female in a contraceptive effective amount, microparticles containing a non-abortifacient contraceptive agent in a biocompatible and biodegradable matrix material and being of a size wherein the natural transport mechanism of the internal female reproduction organs will convey the microparticles across the cervix into the uterus, and allowing said mechanism to so convey the microparticles whereby the contraceptive agent is directly delivered to the uterus and/or fallopian tubes by subsequent release from 5 12. A preparation as claimed in Claim 11 wherein the antigen or antibody constitutes 10 to 60% by weight of the antigen or antibody containing microparticles. 13. A preparation as claimed in Claim 12 wherein the antigen or antibody constitutes 10 to 50% by weight of the said microparticles. 10 14. A preparation as claimed in Claim 13 wherein the antigen or antibody constitutes 10 to 25% by weight of the said microparticles. 15. A preparation as claimed in any one of Claims 11 to 13 wherein the said antigen or antibody is a bacterial or viral pathogenic antigen or an antibody corresponding to a bacterial or viral 15 pathogenic antigen. 16. A preparation as claimed in any one of Claims 11 to 14 wherein the said antigen or antibody is an antigenic enzyme involved in the reproductive process. 17. A preparation as claimed in any one of Claims 11 to 14 20 wherein the said antigen or antibody is an antigenic hormone different from the said menstrual cycle regulatory hormone or an embryonic cellular antigen. 18. A preparation as claimed in Claim 11 wherein the said contraceptive agent is a spermicidal compound. 25 19. A preparation as claimed in Claim 18 wherein the spermicidal agent is nonylpheno/ypolyoxyethylene ethynol, Benzethonium chloride or Chlorindanol. 20. A preparation as claimed in Claim 11 wherein the contraceptive agent is a hormone different from the said menstrual cycle 30 regulatory hormone. 21. A preparation as claimed in Claim 20 wherein the contraceptive agent is progesterone, estradiol, norethindrone, norgestrel, ethynodiol di acetate, lynestrenol, medroxy-progesterone acetate, dimethisterone, megestrol acetate, chlormadinone

5. A preparation as claimed in Claim 1 wherein the microparticles are formulated in a solid vaginal suppository.

6. A preparation as claimed in Claim 5 wherein the suppository is 20 a gelatin suppository.

7. A preparation as claimed in Claim 1 wherein the microparticles are formulated in a cream, jelly, foam or liquid suspension.

8. A preparation as claimed in any one of the preceding claims wherein the microparticles are of a size in the range 20 to 70 microns. 25

9. A preparation as claimed in Claim 8 wherein the microparticles are of a size in the range 20 to 60 microns. 10. A preparation as claimed in any one of the preceding claims wherein the matrix material is polyglycolic acid, polylactic acid, copolymer of glycolic and lactic acid, glycerol monostearate or 30 glycerol di stearate. Π. A preparation as claimed in any one of the preceding claims wherein the said pharmaceutical agent comprises an antigen or antibody for active or passive immunization of the internal female reproductive organs, and/or a contraceptive agent.

10. At a rate of 0.5 to 2 mg per day.